Overview

The non-profit organization dedicated to drive treatment development and improve lives of children with ultra rare mutation in PACS2 gene. We fund and coordinate scientific research run globally. The strategy for treatment development is ready. As well as first materials for research (patient derived cells - both fibroblasts and iPSC). Most of Partners are already contracted - i.a. Charles River Laboratories and top Polish Institute of Experimental Biology (Nencki Institute). Now we are in a critical moment of raising seed fund for first research - those can constitute the ground for future grants. If you want to support us - go to our website and discover support options under "Donate"! To learn more on our plan, check "Research&Resources" section.